No, Ingrezza (valbenazine) is NOT indicated for pseudobulbar affect
Ingrezza is FDA-approved exclusively for tardive dyskinesia and chorea associated with Huntington's disease—it has no approved indication for pseudobulbar affect. 1
FDA-Approved Indications
The FDA drug label explicitly states that valbenazine is indicated for:
- Tardive dyskinesia in adults
- Chorea associated with Huntington's disease in adults
There is no mention of pseudobulbar affect in the approved indications 1.
Approved Treatment for Pseudobulbar Affect
Dextromethorphan/quinidine is the FDA-approved medication specifically for pseudobulbar affect, not valbenazine 2, 3. This combination has demonstrated efficacy in treating pathological laughing and crying across multiple neurological conditions including stroke, traumatic brain injury, ALS, and multiple sclerosis.
Clinical Context
While both conditions involve involuntary movements or emotional expressions:
Pseudobulbar affect is characterized by uncontrollable episodes of laughing or crying that are disproportionate to or independent of the patient's actual emotional state, typically occurring with bilateral corticobulbar tract damage 2, 3, 4
Tardive dyskinesia involves involuntary, repetitive movements (typically orofacial) caused by chronic dopamine receptor blockade from antipsychotic medications 1, 5
Important Caveat
The 2019 Beers Criteria notes that dextromethorphan/quinidine should be used with caution in older adults with behavioral symptoms of dementia without pseudobulbar affect, due to limited efficacy in that population and increased risk of falls and drug-drug interactions 6. This underscores the importance of accurate diagnosis—the medication works for true pseudobulbar affect but not for general behavioral symptoms.
Assessment Tools for Pseudobulbar Affect
When evaluating for pseudobulbar affect, validated instruments include:
Patient education about the condition is crucial, as acknowledgment and understanding can defuse potentially uncomfortable social situations 2.